Literature DB >> 5111993

Dopamine: release from the brain in vivo by amantadine.

P F Von Voigtlander, K E Moore.   

Abstract

After dopamine stores in the caudate nucleus of cats were labeled with [(3)H]dopamine, the ventricular system was perfused with artificial cerebrospinal fluid. The addition of amantadine to the perfusing fluid caused a doserelated increase in the concentrations of [(3)H]dopamine appearing in the perfusion effluent. Subthreshold concentrations of amantadine also enhanced the efflux of [(3)H]dopamine induced by electrical stimulation of the caudate nucleus.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5111993     DOI: 10.1126/science.174.4007.408

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  23 in total

1.  On the synchronizing effect of amantadine-1-hydrochlorid (Symmetrel) on pathological EEG-activity.

Authors:  J Vardi; M Streifler
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

Review 3.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

4.  Traumatic brain injury reduces striatal tyrosine hydroxylase activity and potassium-evoked dopamine release in rats.

Authors:  Samuel S Shin; Eric R Bray; Cathy Q Zhang; C Edward Dixon
Journal:  Brain Res       Date:  2010-11-01       Impact factor: 3.252

Review 5.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

6.  Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study.

Authors:  C Colosimo; M Merello; F E Pontieri
Journal:  J Neurol       Date:  1996-05       Impact factor: 4.849

Review 7.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 8.  Tremor-predominant Parkinson's disease. Approaches to treatment.

Authors:  J Marjama-Lyons; W Koller
Journal:  Drugs Aging       Date:  2000-04       Impact factor: 3.923

9.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 10.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.